Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

Exclusion Criteria

• •Concurrent malignancy or metastatic malignancy of any kind
• •Ongoing chemotherapy, radiation therapy, or other cancer-related treatment
• •History of a bleeding tendency or current use of Coumadin or other anticoagulants
• •Current or previous history of liver, gastrointestinal, hematopoietic, cardiac or renal disease, viral, bacterial, atypical or fungal infections of any organ system and human immunodeficiency virus (HIV) infection
• •Pregnant or lactating women
• •Concurrent use of hormonal contraception or hormone replacement therapy
• •Concurrent use of immunosuppressant medications
• •Concurrent use of medications known to inhibit or induce hepatic enzyme cytochrome P450 (CYP) 3A4
• •Barriers to fine needle aspiration sampling of breast adipose, including breast implants, history of radiation to both breasts, bilateral mastectomies, and/or insufficient breast adipose tissue for adequate fine needle aspiration (FNA) sampling
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypertension, or psychiatric illness/social situation that would limit compliance with study requirements
• •Chronic use of any herbal or dietary supplement containing curcumin or curcuminoids within the 3 months prior to entry on the study or any other supplements that might interact with NEC
• •Known sensitivity or allergy to turmeric spices or curry
• •Dietary intake of large amounts of curry, turmeric spices or black pepper on a regular basis
• •Subjects on a standing regimen of full dose aspirin (\>= 325 mg/day), non-steroidal anti-inflammatory drug (NSAID)s or NSAID-containing products